Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
The levels of osteoprotegerin (OPG), interleukin 18 (IL-18) and soluble interleukin 2 receptor (sIL-2R) in serum during chemotherapy of lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004
Clinical value of soluble interleukine-2 receptor (sIL-2R) serum level examination in the pulmonary sarcoidosis (PS) Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003
Serum levels of vascular endothelial growth factor (VEGF) are elevated in patients with acute exacerbated COPD Source: Eur Respir J 2005; 26: Suppl. 49, 350s Year: 2005
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Late-breaking abstract: Serum concentrations of new factors (IL-20, galectin 3, IL-29 and IL-33) involved in angiogenesis in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer Year: 2011
Soluble interleukin 2 receptor ( sIL-2R ) during chemotherapy of the lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
A serum level of IGF-I, IGF-II and IGFBP-3 in patients with small cell lung cancer (SCLC) during chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 86s Year: 2006
Serum levels of angiopoietin-1, angiopoietin-2 and their receptor- Tie-2 in patients with non small cell lung cancer during chemotherapy Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
Serum levels of TGFβ and VEGF in lung cancer patients and healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 43s Year: 2004
The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF) Source: Eur Respir J 2004; 24: Suppl. 48, 553s Year: 2004
Overexpression of B cell activating factor (BAFF) in peripheral lung of COPD patients Source: Annual Congress 2009 - Pathology and immunology of COPD Year: 2009
The clinical significance of serum osteoprotegerin (OPG) and pro-gastrin-releasing peptide (ProGRP) concentrations in lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004
Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001
Serum levels of vascular endothelial growth factor in lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004